Incyte Corporation vs Paychex, Inc. — how do they compare? Incyte Corporation trades at $115.7 (market cap $23.11B), while Paychex, Inc. trades at $115.19 (market cap $40.98B). The key difference: Paychex, Inc. is the larger of the two by market cap, and Paychex, Inc. pays a 4.13% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | PAYX | |
|---|---|---|
Market Cap | $23.11B | $40.98B |
Sector | Health | Industrials |
52-Week High | $118.52 | $147.99 |
52-Week Low | $67.38 | $85.57 |
Enterprise Value | $19.13B | $44.47B |
Dividend Yield | — | 4.13% |
Trailing returns across standard periods
Latest headlines on both assets
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →